Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Study of Extended Field IMRT External Beam Irradiation and Intracavitary Brachytherapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have carcinoma of the uterine cervix.~* Patients with squamous cell, adenocarcinoma, and adenosquamous carcinoma are eligible.~* International Federation of Gynecology and Obstetrics (FIGO) Stage I to IVA~* Patients must have no evidence of metastatic disease outside of the pelvis (except to the para-aortic nodes), by PET.~* Patients must have a Karnofsky Performance Status of \>= 60 and no medical contraindications to the administration of chemotherapy.~* Age \>= 18.~* Adequate bone marrow function: white blood cells (WBC) \>= 4000/mm3, platelets \>= 100,000 mm3.~* Adequate renal function: BUN \<= 25 mg/dl, creatinine \<= 1.2 mg/dl (urinary diversion is permitted to improve renal function).~* Patients must have bilirubin \<= 1.5 mg/dl.~* Signed study-specific informed consent.~Exclusion Criteria:~* No positive lymph nodes by FDG PET~* Positive supraclavicular lymph nodes by FDG PET Scan or evidence of more distant disease.~* FIGO Stage IVB+ Cervical Cancer~* No prior (within 5 years) or simultaneous malignancies (other than cutaneous basal cell carcinoma).~* Karnofsky Performance Status \<60.~* Patients with significant medical illness preventing the use of full dose chemotherapy are excluded.~* Patients with the following histologies are excluded: small cell, carcinoid, glassy cell, clear cell and adenoid cystic.~* Life expectancy \< 6 months.~* Patients with poorly controlled diabetes mellitus (fasting blood glucose level \> 200 mg/dL) are not eligible.~* No prior surgery for treatment of disease other than exploratory laparotomy or biopsy.~* No previous systemic chemotherapy.~* No pelvic radiation therapy is permitted other than transvaginal irradiation to control bleeding.~* Pregnant women are ineligible and those of child-bearing potential should practice contraception.~* Patients with abnormal liver function tests

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Group 1 (Type: EXPERIMENTAL): Pelvic Lymph Nodes Only Positive on FDG PET.~IMRT External Beam radiation to the para-aortic region (45 Gy)~Pelvis intracavitary brachytherapy (6 HDR treatments)~Weekly cisplatin 40 mg/m\^2
- Treatment Group 2 (Type: EXPERIMENTAL): Para-Aortic Lymph Nodes Positive on FDG PET~IMRT (50.4 Gy to para-aortic lymph node bed with a 10.8 Gy boost to nodes)~IMRT external beam pelvic radiation therapy as appropriate for stage~Intracavitary brachytherapy (6 HDR treatments)~Weekly cisplatin (40 mg/m\^2)

Based on this trial design, predict the completion outcome and termination type (if applicable).